ABS Biotechnologies GmbH utilizes next-generation stem cell technology and human blood vessel cells to create a drug screening platform that predicts cardiovascular drug side effects. This approach enhances the safety profile of new treatments, addressing the critical need for precision medicine in drug development.
Funding
Funding not disclosed
Founders
Product
Problem
Cardiovascular drug side effects are a major concern in drug development, often detected late in the process or after the drug has reached the market. Traditional drug screening methods may not accurately predict these side effects in humans, leading to costly failures and potential harm to patients.
Solution
ABS Biotechnologies offers a drug screening platform that utilizes next-generation stem cell technology and human blood vessel cells to more accurately predict cardiovascular drug side effects. By using human cells with unique functionality, the platform provides a more relevant and predictive assessment of drug safety compared to traditional methods. This approach enables the development of safer treatments by identifying potential cardiovascular issues early in the drug development pipeline. The platform aims to improve the safety profile of new treatments and contribute to precision medicine.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions involved in cardiovascular drug development.
Features
- Utilizes human induced pluripotent stem cells (iPSCs) to generate human blood vessel cells.
- Offers a repertoire of human cells with unique functionality for cardiovascular safety assessment.
- Provides a platform for predicting major cardiovascular drug side effects.
- Employs next-generation stem cell technology for enhanced accuracy and relevance.